Eltanexor

DRUG2 trials

Sponsors

Azienda Ospedaliero Universitaria Delle Marche, Vanderbilt-Ingram Cancer Center

Conditions

Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRelapsed Myelodysplastic Syndrome

Phase 1

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

RecruitingNCT06399640

Vanderbilt-Ingram Cancer CenterAcute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia +2

Start: 2024-08-14End: 2027-10-01Target: 60Updated: 2026-08-19

Phase 2

A phase 2A pilot study to assess the safety and efficacy of eltanexor in relapsed/refractory NPM1-mutated acute myeloid leukemia

RecruitingCTIS2024-514724-16-01

Azienda Ospedaliero Universitaria Delle MarcheAcute Myeloid Leukemia

Start: 2025-01-14Target: 10Updated: 2025-12-22

Related Papers

Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood2024-11-051 citations